105 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
in employee related costs related to hiring activities to support the launch of SYFOVRE, an increase in commercialization related activity
8-K
EX-1.1
h95onzcax03ig1dgsp
1 Nov 23
Entry into a Material Definitive Agreement
7:59am
424B5
p7t4vre xyy50t
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
EX-99.1
1vrni2ri21
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
8-K
EX-1.1
mlva8g2q8bbpbbmb7xie
24 Mar 22
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8:18pm
424B5
f73x8whn 6inket
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
fytxfwxkiivbs7xk
23 Mar 22
Prospectus supplement for primary offering
5:14pm